VAXCHORA Pediatric Study
Status: | Active, not recruiting |
---|---|
Conditions: | Infectious Disease |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 2 - 17 |
Updated: | 7/27/2018 |
Start Date: | July 21, 2017 |
End Date: | October 2020 |
A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age
VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against
disease caused by Vibrio cholerae serogroup O1. VAXCHORA is approved for use in adults 18
through 64 years of age travelling to cholera-affected areas. The primary goals of this Phase
4 study is to evaluate the safety and immunogenicity of VAXCHORA in children ages 2 years to
<18 years of age in developed countries.
disease caused by Vibrio cholerae serogroup O1. VAXCHORA is approved for use in adults 18
through 64 years of age travelling to cholera-affected areas. The primary goals of this Phase
4 study is to evaluate the safety and immunogenicity of VAXCHORA in children ages 2 years to
<18 years of age in developed countries.
Inclusion Criteria:
- Male or Female
- Between 2 and <18 years of age on Day 1
- In general good health
- Able and willing to provide informed assent for study participation
- Primary caregiver is able and willing to provide informed consent for study
participation
- (for females of childbearing potential) Using an acceptable method of contraception
through Day 29
Exclusion Criteria:
- Current acute gastrointestinal illness or loose stools within 3 days of Day 1 visit
- Current acute febrile illness
- History of cholera infection
- History of cholera vaccination
- History of severe allergic reaction (e.g. anaphylaxis) to any ingredient of VAXCHORA
- Congenital or acquired immunodeficiency
- Pregnancy (for females of childbearing potential)
- Any other condition that, in the opinion of the Investigator, creates an unacceptable
risk to the subject
- Any other condition that, in the opinion of the Investigator, will interfere with the
conduct of the study or the validity of the data
- Duration of >2 weeks of abnormal stool pattern, defined as <3 stools per week or >2
stools per day in the past 6 months
- Regular use of laxatives in the past 6 months
- History of enterotoxigenic E. coli infection
- Travel to cholera-endemic area in the previous 5 years
- Nursing/Breastfeeding
- Received or plans to receive the following from 14 days prior to the study vaccination
through 11 days after vaccination: Any other licensed vaccines, antibiotics, or
chloroquine
- Received or plans to receive any other investigational agent throughout the main study
(Day 181)
We found this trial at
10
sites
Lexington, Kentucky
859) 257-9000
Principal Investigator: Richard Greenberg, MD
Phone: 859-323-5015
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Evan Anderson, MD
Phone: 404-727-3769
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials
1709 S Rock Rd
Wichita, Kansas 67207
Wichita, Kansas 67207
316-689-6629
Principal Investigator: Terry Klein, MD
Phone: 316-689-6685
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Elizabeth Barnett, MD
Phone: 617-414-5813
Click here to add this to my saved trials
Click here to add this to my saved trials
Kansas City, Missouri 64114
Principal Investigator: John Ervin, MD
Phone: 816-943-0770
Click here to add this to my saved trials
Lenexa, Kansas 66219
Principal Investigator: Carlos A Fierro, MD
Phone: 913-825-4405
Click here to add this to my saved trials
Mount Pleasant, South Carolina 29464
Principal Investigator: Cynthia Strout, MD
Phone: 843-856-5141
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Stephen Sharp, MD
Phone: 615-329-0197
Click here to add this to my saved trials
Rochester, New York 14609
Principal Investigator: Matthew G Davis, MD
Phone: 585-288-0890
Click here to add this to my saved trials